Roche's Enspryng Gets FDA Priority Review for Thyroid Eye Disease

Roche (OTC: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Enspryng (satralizumab) for the treatment of thyroid eye disease (TED) and granted it priority review. The FDA decision is expected by October 2026.

Details of the Regulatory Action

Priority review is a designation that expedites the FDA's review of drugs that treat serious conditions and offer significant improvements over available therapies. The application is based on data from a phase III clinical trial that demonstrated Enspryng's efficacy in reducing TED symptoms, including proptosis (eye bulging) and inflammation.

Company's Position

Roche expressed confidence in Enspryng's data, noting that the drug could provide a new treatment option for patients with TED, a rare autoimmune condition affecting the eyes. The company highlighted the unmet medical need, as current treatments are limited.

Precedents and Context

Enspryng is already approved in the U.S. for neuromyelitis optica spectrum disorder (NMOSD). If approved for TED, it would compete with Horizon Therapeutics' Tepezza, currently the only FDA-approved therapy for the condition. Tepezza generated over $2 billion in sales in 2025.

Potential Financial Impact

Roche has not provided specific revenue guidance, but analysts estimate that approval could add several hundred million dollars annually to Enspryng's sales, given the high cost of biologic therapies and the limited competition.